Pursuant to the provisions of Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Johnson Pharmacare Ltd held a Board meeting on May 27, 2026, where the audited financial results for Q4 and FY ended March 31, 2026 were approved. The company reported total income of Rs. 158.10 lakhs and a massive net loss of Rs. 5,561.06 lakhs for FY2026, compared to a loss of Rs. 58.38 lakhs in FY2025. Total assets declined significantly to Rs. 2,203.11 lakhs from Rs. 5,792.59 lakhs. Two directors - Rajendra Prasad (Non-Executive) and Umesh Kumar (Executive) - resigned effective April 17, 2026 citing personal reasons. The statutory auditor raised qualifications noting non-compliance with Ind AS, non-provision of interest on loans, and significant going concern doubts with cash losses of Rs. 11,123.52 lakhs. Pending tax demands of Rs. 351+ lakhs across multiple assessment years were also flagged.
This is a highly negative development. The company is reporting severe losses, declining assets, and auditor doubts about its ability to continue as a going concern. Shareholders should be extremely cautious as the stock carries high risk of value erosion.